Very recently, Winkler et al. have shown that in high-grade serous ovarian carcinoma specimens before platinum-based chemotherapy treatment, the SLFN11 density at the protein level in both the neoplastic and microenvironmental components was independently associated with a favorable outcome and that SLFN11 expression in both infiltrating innate and adaptive immune cells was associated with immune activation in HGSOC [61]. This evidence concerns the gene SLFN11 and ovarian serous carcinoma.